Esperion partners with CSL Seqirus to market cholesterol drugs in Australia/New Zealand

From Nasdaq: 2025-03-03 09:11:52

Esperion Therapeutics has signed a deal with CSL Seqirus to exclusively market NEXLETOL and NEXLIZET in Australia and New Zealand. The agreement includes upfront and milestone payments of up to $5 million. Both companies aim to improve access to cardiovascular treatments. ESPR stock is up 1.76% in pre-market trading on the Nasdaq.



Read more at Nasdaq: Esperion Bags $5 Mln CSL Seqirus Deal To Commercialize Cholesterol Drugs In Australia, New Zealand